/Investor DB

ZhenFund — 2021 Investments

3 investments dated 2021 · listed companies and verified rows first · show all

Accutar Biotechaccutarbio.cominApr 2021

Accutar Biotech applies artificial intelligence to drug discovery, using a hybrid approach of computational drug design followed by wet lab validation to reduce the time and cost of developing new drugs.

AI & Machine LearningBiotechDeep TechNew York, US

Jie Fan(Founder)inWei He(Executive Officer)Yimin Qian(Executive Officer)Xiangyan Sun(Executive Officer)Quan Zhou(Director)Long Zhu(Director)

Co-investors5Y CapitalCoatue ManagementIDG CapitalYF Capital

CellXcellx.techSeed · Mar 2021 · $4M

CellX offers a self-service operations management platform that automates repetitive tasks such as 24/7 order intake, multi-channel order and message handling, order status tracking, and after-sales ticket workflows.

E-commerceEnterprise SoftwareSaaS

Ziliang Yang(Founder)in

Co-investorsBetter Bite VenturesSky9 CapitalAgronomicsLever VCSALT

Redesign Scienceredesignscience.cominDec 2021 · $15M

Software platform to improve drug discovery

AI & Machine LearningBiotechDeep TechNew York, US

David William Rooklin(Executive Officer, Director)Haotian Li(Director)

Co-investorsCollaborative FundHAWKTAILNotation CapitalNYU Innovation Venture FundAcequia Capital (AceCap)Preface Ventures+2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.